Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25635546 | 0.90 | TLR7 (0.67) | TLR7TLR8PIM3 | |
| Cpg-52852 SCHEMBL29371102 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL483385 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL29182347 | 0.86 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL20284105 | 0.86 | TLR7 (0.73) | TLR7TDP1TLR8PIM3 | |
| SCHEMBL3884418 | 0.85 | TLR7 (0.72) | TLR7TDP1TLR8 | |
| SCHEMBL3243678 | 0.85 | TLR7 (0.70) | TLR7TDP1TLR8PIM3PIM1 | |
| SCHEMBL3888482 | 0.84 | TLR7 (0.67) | TLR7TDP1TLR8POLB | |
| SCHEMBL4523563 | 0.84 | TLR7 (0.69) | TLR7TDP1TLR8 | |
| SCHEMBL9070687 | 0.83 | TLR7 (0.68) | TLR7TDP1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9161946-B2 | Dosing methods for treating disease | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9161946-B2 | Dosing methods for treating disease | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20110166092-A1 | DOSING METHODS FOR TREATING DISEASE | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166092-A1 | DOSING METHODS FOR TREATING DISEASE | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166092-A1 | DOSING METHODS FOR TREATING DISEASE | TLR7, TLR9, TLR1 | TLR7 1/4885TDP1 802/4885TLR8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.